UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review

International journal of molecular sciences, 2022-07, Vol.23 (13), p.7079

2022

Volltextzugriff (PDF)

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Scientific reports, 2015-12, Vol.5 (1), p.18670-18670, Article 18670

2015

Volltextzugriff (PDF)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis

BMC cancer, 2022-06, Vol.22 (1), p.623-623, Article 623

2022

Volltextzugriff (PDF)

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

Biomedicines, 2023-01, Vol.11 (1), p.109

2023

Volltextzugriff (PDF)

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials

BMC cancer, 2020-05, Vol.20 (1), p.418-10, Article 418

2020

Volltextzugriff (PDF)

Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients

International journal of molecular sciences, 2024-02, Vol.25 (5), p.2490

2024

Volltextzugriff (PDF)

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

Frontiers in oncology, 2022-12, Vol.12, p.1016295

2022

Volltextzugriff (PDF)

Are All Patients Truly Hormone Receptor Negative?

Journal of clinical oncology, 2017-05, Vol.35 (14), p.1627-1627

Moscetti, Luca

2017

Volltextzugriff (PDF)

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

Journal of experimental & clinical cancer research, 2011-01, Vol.30 (1), p.10-10, Article 10

2011

Volltextzugriff (PDF)

Management of PALB2‐associated breast cancer: A literature review and case report

Clinical case reports, 2023-08, Vol.11 (8), p.e7747-n/a

2023

Volltextzugriff (PDF)

Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications

Oncotarget, 2018-08, Vol.9 (60), p.31606-31619

2018

Volltextzugriff (PDF)

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Breast cancer research and treatment, 2014-10, Vol.147 (3), p.599-607

2014

Volltextzugriff (PDF)

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

Oncotarget, 2017-08, Vol.8 (33), p.54528-54536

2017

Volltextzugriff (PDF)

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study

Journal of Cancer, 2014-01, Vol.5 (5), p.320-327

2014

Volltextzugriff (PDF)

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

ESMO open, 2020, Vol.5 (4), p.e000856, Article e000856

2020

Volltextzugriff (PDF)

Lapatinib and chronic renal insufficiency: Lapatinib e insufficienza renale cronica

Aboutopen, 2018-03, Vol.4 (1), p.5-7

Moscetti, Luca

2018

Volltextzugriff (PDF)

Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes

International journal of clinical oncology, 2013-04, Vol.18 (2), p.343-349

2013

Volltextzugriff (PDF)

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

European journal of cancer (1990), 2023-09, Vol.190, p.112944-112944, Article 112944

2023

Volltextzugriff (PDF)

Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist

Clinical breast cancer, 2022-06, Vol.22 (4), p.289-299

2022

Volltextzugriff (PDF)

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

Cancer management and research, 2018-01, Vol.10, p.91-103

2018

Volltextzugriff (PDF)

Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e12516-e12516

2021

Volltextzugriff (PDF)

TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e13010-e13010

2021

Volltextzugriff (PDF)

1 – 25 von 127

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis Online

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(113)
Mit Volltextzugriff
(120)

Publikationsform

Sprache

Englisch
(127)

Erscheinungsjahr

n.n

Thema

Science & Technology
(83)
Life Sciences & Biomedicine
(79)
Oncology
(62)
Humans
(53)
Female
(45)
Breast Cancer
(39)
Aged
(34)
Middle Aged
(31)
Adult
(26)
Chemotherapy
(24)
Treatment Outcome
(23)
Cancer Therapies
(20)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(19)
Breast Neoplasms - Drug Therapy
(19)
Metastasis
(19)
Patients
(19)
Aged, 80 And Over
(17)
Retrospective Studies
(17)
Breast Neoplasms - Pathology
(16)
Male
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(16)
Cancer Research
(7)
Tumori
(7)
Oncotarget
(6)
Scientific Reports
(6)
Clinical Breast Cancer
(5)
Journal Of Cellular Physiology
(5)
Breast Cancer Research And Treatment
(4)
Transfusion
(4)
Bmc Cancer
(3)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review

Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis

Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges

Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: to prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials

Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients

Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study

Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy

Are All Patients Truly Hormone Receptor Negative?

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

Management of PALB2‐associated breast cancer: A literature review and case report

Genomic alterations at the basis of treatment resistance in metastatic breast cancer: clinical applications

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Fulvestrant 500 milligrams as endocrine therapy for endocrine sensitive advanced breast cancer patients in the real world: the Ful500 prospective observational trial

Eribulin mesylate in pretreated breast cancer patients: a multicenter retrospective observational study

Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects

Lapatinib and chronic renal insufficiency: Lapatinib e insufficienza renale cronica

Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes

Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

Ocular Toxicity in Breast Cancer Management: Manual for The Oncologist

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis

TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis

Aktive Filter

Suchergebnisse filtern